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Congenital central hypoventilation syndrome
(CCHS, Ondine’s curse, Mendelian Inheritance
in Man (MIM) 209880) is a rare disease with an
estimated prevalence of 1 in 200,000 live births.1
CCHS, first reported by Mellins et al in 1970, is
characterized by dysfunctions in the autonomic
nervous system with failure of ventilation regula-
tion.2 The clinical manifestations of CCHS pres-
ent with variable degrees of severity, which may
range from complete apnea during sleep, severe
hypoventilation during wakefulness, to mild hy-
poventilation during quiet sleep only.3 Previous
reports showed that CCHS may be associated
with Hirschsprung’s disease or tumor of neural
crest origin.1,3–5 A common pathogenesis involv-
ing neural crest-derived cell lineages has been
suggested.5 Specifically, the paired mesoderm
homeobox protein 2b (PHOX2B) gene is impor-
tant in the development of the autonomic nerv-
ous system, including all derivatives from the
autonomic neural crest.6 Recent studies have iden-
tified the PHOX2B gene as the major gene in-
volved in CCHS.6–9 Here, we report a neonate with
typical manifestations of CCHS with PHOX2B
gene mutation detected by polymerase chain 
reaction (PCR).
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Congenital central hypoventilation syndrome (CCHS) is a rare disease that is characterized by failure in
the autonomic control of breathing. Recent reports have identified mutation of the paired mesoderm
homeobox protein 2b (PHOX2B) gene as playing a major role in CCHS. Increasing polyalanine repeat
number is associated with a more severe clinical phenotype. We report a newborn male infant with the
clinical manifestations of apnea and cyanosis requiring immediate endotracheal intubation at the age of 
1 day. Recurrent hypoventilation with hypercapnia and hypoxemia occurred during sleep after weaning
from the ventilator. No primary cardiopulmonary disease was identified. These clinical manifestations are
compatible with CCHS. PHOX2B gene mutation analysis performed at the age of 4 months revealed ex-
panded alleles containing polyalanine 26 repeats, further supporting the diagnosis of CCHS. Continuous
ventilator support was necessary and tracheostomy was ultimately performed at the age of 5 months due
to ventilator dependence. He was discharged with home ventilator support at the age of 6 months. 
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CASE REPORT
Case Report
A male infant was born to a 34-year-old, G4P1SA3
mother at the gestational age of 39 weeks at a
local hospital. Body weight, body length and head
circumference at birth were appropriate for ges-
tational age. After delivery, endotracheal tube in-
tubation was required because of frequent apnea
and cyanosis. Extubation was performed on the
next day after his condition stabilized. However,
recurrent apnea with cyanosis while sleeping was
noted later on the same day and intubation was
performed again. Abdominal distension was also
noted. Due to persistent apnea and ventilator 
dependence, he was transferred to our hospital
for further evaluation and management.
Physical examination on admission revealed
a generally normal newborn. However, frequent
hypercapnia with PaCO2 > 60 mmHg was noted
even under a low rate ventilator setting. Bron-
choscopic examination showed normal airway
structure except for subglottic erosion at the an-
terior cricoid level with a mild degree of granu-
loma in the bilateral vocal cord process. A series
of studies including cardiac echography, brain
magnetic resonance imaging, chest X-ray, and
metabolic survey with tandem mass spectrome-
try and urine gas chromatography revealed normal
findings. CCHS was suspected. Polysomnography
was arranged but the family refused this exami-
nation due to frequent apnea and cyanosis when
ventilator support was discontinued. Because of
abdominal distension, lower gastrointestinal se-
ries was performed to exclude the possibility of
Hirschsprung’s disease associated with CCHS.
Intestinal suction biopsy was performed and the
presence of ganglion cells with normal thioacetyl-
cholinesterase stain on pathology ruled out the
diagnosis of Hirschsprung’s disease. Prokinetic
agents and continuous feeding were used to im-
prove gastrointestinal symptoms. The diagnosis
of neuroblastoma was also excluded due to nor-
mal 24-hour urinary vanillylmandelic acid.
During the following months of hospitaliza-
tion, the family was initially reluctant to allow
tracheostomy for their baby. Assisted ventilation
via nasal prong or endotracheal tube was required
due to frequent apnea and hypoventilation. These
episodes were frequently complicated with hy-
percapnia or hypoxemia. Tracheostomy was ulti-
mately performed at the age of 5 months after
discussion with the family. The infant was dis-
charged 1 month later with home ventilator 
support. He demonstrated normal growth and
development. PHOX2B gene mutation analysis
was performed to confirm the diagnosis of CCHS.
DNA preparation, PCR amplification and
sequencing
A DNA sample was extracted from peripheral
blood by using the Puregene DNA Isolation Kit
(Gentra Systems Inc., Minneapolis, MN, USA)
according to the manufacturer’s instructions. To
detect the PHOX2B gene, the intronic primer pair
5’-CTCGGGCAAAAAGTCTGA-3’ (forward) and
5’-GTCTTTGGAGCGAAGATAGG-3’ (reverse) span-
ning exon 3 of the PHOX2B gene was used. This
primer pair combination generated a 389-bp frag-
ment. PCR techniques for the DNA fragments were
performed in a total volume of 25 μL containing
50 ng of genomic DNA, 0.12 μM of each primer,
100 μM dNTPs, 8% DMSO, 0.5 units of AmpliTaq
Gold enzyme (PE Applied Biosystems, Foster City,
CA, USA), and 2.5 μL of GeneAmp 10× buffer II
(10 mM tris-HCl, pH = 8.3, 50 mM KCl), in 2 mM
MgCl2 as provided by the manufacturer.
Amplification was performed in a multiblock
system (MBS) thermocycler (ThermoHybaid,
Ashford, UK). PCR amplification was performed
with an initial denaturation step at 95°C for 10
minutes, followed by 35 cycles consisting of de-
naturation at 94°C for 30 seconds, annealing at
56°C for 45 seconds, and extension at 72°C for
45 seconds, and then a final extension step at
72°C for 10 minutes.
For sequence analysis, the PCR products were
purified by solid-phase extraction, and bidirection-
ally sequenced using the Taq DyeDeoxy termina-
tor cycle sequencing kit (Applied Biosystems)
according to the manufacturer’s instructions. Se-
quencing reactions were separated on an Applied
Biosystems 3100 sequencer. The pedigree and 
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results of the sequence analysis are shown in the
Figure. PHOX2B gene study yielded expanded 
alleles containing polyalanine 26 repeats in this
patient.
Discussion
CCHS is a rare disease that is characterized by
the absence of adequate autonomic respiratory
control. The International Classification of Sleep
Disorders proposed diagnostic criteria for CCHS,10
which include the following: (1) the patient ex-
hibits shallow breathing or cyanosis and apnea,
the signs are worse during sleep than in wakeful-
ness and their onset is during the perinatal period;
(2) hypoventilation is worse during sleep than in
wakefulness; (3) ventilatory response to hypoxia
and hypercapnia is absent or diminished; (4) poly-
somnographic monitoring during sleep demon-
strates hypercapnia and hypoxia, predominantly
without apnea; (5) no primary lung disease or
ventilatory muscle dysfunction can explain the
hypoventilation; and (6) the symptoms are not
due to any other sleep disorder, such as infant
sleep apnea. The minimal set of criteria to be met
for the diagnosis are (1), (2), (5) and (6).10
The clinical outcome of CCHS is variable. An
overall mortality rate of 38% was reported in a
French series of 70 patients with CCHS.1 Infants
with CCHS may present with hypoventilation of
variable severity ranging from complete apnea
during sleep, severe hypoventilation during wake-
fulness, to mild hypoventilation during sleep.
These infants also tend to show a lack of ventila-
tory sensitivity to hypercapnia and hypoxia that
may result in progressive pulmonary hyperten-
sion, cor pulmonale and central nervous system
hypoxic damage.11 Sudden infant death syndrome
may be related to this rare disease. Monitoring 
of respiratory physiology using methods such 
as polysomnography has been recommended to
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c.757 ins (GCN)6
GCG
GCC GCG GCG GCGGCA GCG
Genomic sequence GCG GCG GCA GCG GCAGCG GCG
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Figure. DNA sequencing of the PHOX2B gene shows expanded alleles containing polyalanine 26 repeats in the patient.
identify if there is spontaneous breathing during
rapid eye movement (REM) sleep, non-REM sleep
and wakefulness.3,10 In our patient, polysomnog-
raphy was difficult to perform because of the
manifestations of severe apnea and cyanosis when
ventilator support was discontinued.
CCHS has been reported in association with
several other disorders such as Hirschsprung’s
disease (15–20%),1,3,4 neuroblastoma (3%) and
growth hormone deficiency (< 1%).1 This reflects
a common molecular pathogenesis involving de-
fects of one or more genes that control the devel-
opment of neural crest-derived cell lineages.5 In
our patient, abdominal distension was noted in
early infancy. Hirschsprung’s disease was suspected
initially but was then excluded by the pathologic
evidence of ganglion cells in the rectum. The pa-
tient also had normal 24-hour urinary vanillyl-
mandelic acid that excluded the possibility of
neuroblastoma.
Genetic roles in the pathogenesis of CCHS
have been widely investigated. Genes involved in
the development of the autonomic nervous sys-
tem, such as the rearranged during transfection
(RET) proto-oncogene, glial-derived neurotrophic
factor gene (GDRF), the endothelin 3 gene, the
brain derived neutrotrophic factor (BDNF) and 
T-cell leukemia, homeobox 3 (Tlx-3) genes, have
previously been examined. However, only a few
mutations were found to be related.12–16 Amiel 
et al first demonstrated that a significant number
of individuals with CCHS showed mutations in
the PHOX2B gene.6 In addition, the mutation de-
tection rate was over 90% among patients who
had CCHS.7,9 The PHOX2B gene in humans is 
located in chromosome 4p12, encoding a 314
amino acid paired box homeodomain transcrip-
tion factor, with two short and stable polyalanine
repeats of nine and 20 residues, which is expressed
in the developing hindbrain and the peripheral
nervous system as well as in all noradrenergic cen-
ters and visceral motor and branchiomotor neu-
rons of the cranial nerves.9 The inheritance pattern
is autosomal dominant.7 De novo mutation was
noted in most cases. Polyalanine expansions are the
most common mutations in patients who have
CCHS.6,7,9 Frameshift mutation, nonsense muta-
tion or missense mutation have also been reported
in CCHS.6 In addition, genotype–phenotype cor-
relation has been described in patients who have
CCHS. Increasing polyalanine repeat number is
associated with a more severe clinical pheno-
type.7,9 A somatic mosaicism has been detected
in 4.5% of parents whose children have CCHS.17
This information is important for genetic coun-
seling. Because the percentage of germline mo-
saicism is unknown, the risk of recurrence cannot
be predicted accurately.18 Our patient had an 
expanded allele containing polyalanine 26 repeats
in the PHOX2B gene. Both of his parents had a
normal PHOX2B gene polyalanine pattern. The
assay for PHOX2B polyalanine repeat mutation
represents a highly sensitive and specific tech-
nique for confirming the diagnosis of CCHS.7,17
Our review of the literature found no previous
reports of CCHS confirmed by PHOX2B gene
mutation analysis from Taiwan.
In summary, diagnosis of CCHS in the past
has usually relied on the patient’s clinical mani-
festations. Analysis of PHOX2B gene mutation is
a precise and rapid method for the diagnosis of
CCHS. Further application of gene study in the
diagnosis of patients who may have CCHS and
in genetic counseling of the parents is highly rec-
ommended in Taiwan.
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